You are here

Metabolic Diseases & Cardiovascular Risk Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with metabolic diseases and at cardiovascular risk. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Cardiovascular & Metabolic Diseases Pipeline as of

  • Discovery Projects
  • Phase 1
    5
  • Phase 2
    0
  • Phase 3
    0
  • Registration
    1
  • Total6
 
Compound Name
Indication
Phase
Submission Type
Compound Type
ertugliflozin (PF-04971729)
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SGLT-2 Inhibitor
Go to clinical trial
Diabetes Mellitus-Type 2 Registration New Molecular Entity Small Molecule
PF-05221304
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) (FAST TRACK) Phase 1 New Molecular Entity Small Molecule
PF-06427878
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Go to clinical trial
Hyperlipidemia Phase 1 New Molecular Entity Small Molecule
PF-06667272
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Myeloperoxidase Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH)
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-06835919
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Ketohexokinase (KHK) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 1 New Molecular Entity Small Molecule
PF-06865571
Therapeutic Area:
Metabolic Disease and Cardiovascular Risks
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 1 New Molecular Entity Small Molecule